Industry study suggests data exclusivity vouchers will not provide a complete incentive for new antimicrobial drug R&D
Photo credits: WHO
A voucher system to incentivise the development of new antibiotics, proposed as part of the ongoing reform to the EU’s pharmaceutical legislation, would cost 45% less than previously thought, thanks to changes suggested by the European Parliament.
But these changes would also make the voucher system less effective, according to research commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
“The good news for member states is this has reduced the cost,” said Tim Wilsdon of Charles River Associates, a co-author of the research report. “The bad news is, obviously we still need an incentive that encourages antimicrobials, so it’s got to be made up somewhere else.”
Discover the latest in research funding every Tuesday with Funding Newswire. Dive into detailed articles with our monthly or yearly subscriptions or start with a free trial
NOTE: if you're a part of one of our Network member organisations, you get free access by signing up with your institutional email. Verify your eligibility here.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.